- Home
- ALT vs NB Comparison
ALT vs NB Comparison
Compare ALT & NB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | NB |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.8M | 562.0M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ALT | NB |
|---|---|---|
| Price | $3.06 | $3.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $17.67 | $6.93 |
| AVG Volume (30 Days) | ★ 3.2M | 2.2M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.00 | N/A |
| 52 Week Low | $2.56 | $3.41 |
| 52 Week High | $6.44 | $12.58 |
Technical Indicators
Market Signals| Indicator | ALT | NB |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 35.86 |
| Support Level | $3.02 | $3.41 |
| Resistance Level | $3.09 | $5.71 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 13.16 | 14.61 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About NB NioCorp Developments Ltd.
NioCorp Developments Ltd is engaged in exploration and development of mineral deposits in North America, specifically, the Elk Creek Niobium/Scandium/Titanium property.